Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEUGENE

Financiado

Cerrado

Advanced gene therapy tools for treatment of CNS specific disorders

Curative therapies still do not exist for most CNS diseases but gene therapy is a promising new approach. We propose that it will be possible to modify brain function and pathophysiology by targeted delivery of specific curative f... ver más

31/03/2012

UMG

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

UNIVERSITAETSMEDIZIN GOETTINGEN GEORGAUGUSTU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-03-31 No tenemos la información de la convocatoria

0% 75% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

UMG

0.00€ | Lider

RHUL

N.D. | Participante

CEA

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BRAINCAV NONHUMAN ADENOVIRUS VECTORS FOR GENE TRANSFER TO THE BRAIN 4M€ Cerrado

GTNCTV Gene therapy and nanotechnology based CNS targeted vectors 2M€ Cerrado

RTLVNHP Mimimally invasive retrograde targeting of aCAR lentiviral v... 165K€ Cerrado

DD-PD A novel mechanism to regulate gene expression in the brain 167K€ Cerrado

RTI2018-097730-B-I00 EXPRESION GENERALIZADA DE TRANSGENES EN INTERNEURONAS INHIBI... 121K€ Cerrado

CG01 A novel gene therapy for epilepsy 5M€ Cerrado

Líder del proyecto

UNIVERSITAETSMEDIZIN GOETTINGEN GEORGAUGUSTU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Curative therapies still do not exist for most CNS diseases but gene therapy is a promising new approach. We propose that it will be possible to modify brain function and pathophysiology by targeted delivery of specific curative factors to selected populations of brain cells that are affected by disease. This opens the door for effective treatment regimes, which can be tailored to individual patients needs. However, currently available gene transfer vectors have limitations regarding safety and efficacy, as they do not allow for targeting of specific populations of neurons or glia or regulation of transgene expression. The NEUGENE consortium has been founded by leading European scientists from academia and industry to overcome these limitations. The consortium will develop Adeno-associated virus (AAV) and Lentivirus (LV)- based tools for targeted and regulated gene transfer into different populations of CNS cells. The consortium will provide a selection of vectors that are optimized for different therapeutic approaches, e.g. regulated expression of neurotrophic factors or manipulation of neurotransmitter synthesis in specific neurons. NEUGENE has three major goals:1) targeting gene transfer vectors to specific populations of neurons and glia, by transcriptional regulation and miRNA-mediated de-targeting and by exploiting the cell-specific tropism of novel types of viral vectors, 2) tight control over expression levels of therapeutic genes by using regulated systems based on different principles, and 3) establishing the safety of the novel vector tools. NEUGENE will verify the functional efficacy of the novel CNS gene transfer tools in a well-established animal model of Parkinson's Disease (PD). This disorder affects over 1.000.000 Europeans and is increasing in prevalence with the aging population. Importantly, principles and mechanisms developed and evaluated within the consortium will also be of direct relevance for gene therapy of many other brain disorder.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores